BioXcel Therapeutics, Inc.
BTAI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.12 | -0.08 | -0.72 |
| FCF Yield | -475.13% | -180.41% | -22.51% | -15.41% |
| EV / EBITDA | -2.00 | -0.74 | -3.19 | -2.85 |
| Quality | ||||
| ROIC | -399.01% | -364.51% | -92.09% | -46.99% |
| Gross Margin | 5.43% | 8.70% | 94.67% | 0.00% |
| Cash Conversion Ratio | 1.21 | 0.87 | 0.82 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | 82.14% | – | – | – |
| Free Cash Flow Growth | 53.54% | -14.43% | -64.02% | -23.90% |
| Safety | ||||
| Net Debt / EBITDA | -1.66 | -0.22 | 0.63 | 2.16 |
| Interest Coverage | -4.44 | -12.90 | -19.44 | -2,673.38 |
| Efficiency | ||||
| Inventory Turnover | 3.16 | 0.63 | 0.01 | 0.00 |
| Cash Conversion Cycle | -2,586.70 | -3,359.79 | -150,193.36 | -5,749.06 |